glyXera
Breathing New Life in Glycoanalysis

Biosimilar drugs are growing in demand owing to their ability to provide additional treatment options at a lower cost. However, due to the high cost and complexity involved in their production, choosing the best clone candidates for subsequent development of cell lines is crucial to release the product in the market in time. In other words, you need to bet on the right horse in a high-stakes game. Traditionally, glycosylation machinery is often overlooked during discovery and early development phase. This often results in the selection of the wrong clones regarding glycosylation. Applying a break-fix model to remediate the issue negatively affects the growth and productivity of the production cell line candidates.

glyXera, a spin-off from Max Planck Society, is a specialized provider of high-performance glycoanalysis in terms of throughput, resolution, sensitivity, reproducibility, and in-depth analysis. glyXera’s patented glyXbox™ technology screens hundreds of clones for the best glycosylation machinery along with retaining tight time frames. glyXbox is a comprehensive set of superior high-performance technology platforms to decipher glycosylation, which is a critical quality attribute for recombinant glycoproteins. “Our platforms enable better and timely decision-making at every stage along the entire lifetime of a product,” says Dr. Erdmann Rapp, Founder, CEO and CSO, glyXera.

glyXera uses separation- and mass-spectrometry-based glycoanalytical tools. It holds substantial experience in providing tailored glycoanalytical products and services to customers for 10 years now. Its expertise guides clients toward improved decision-making, increasing the speed of the discovery phase (e.g. early clone screening), R&D, clinical trials, and approval of products such as biopharmaceuticals/biologics, vaccines, and functional food.

glyXera’s products and services portfolio comprises glycoprofiling at varying analysis depth, monosaccharide analysis, site occupancy analysis, glycopeptide mapping, glycoproteomics, intact mass analysis of glycoproteins, proteomics and general protein characterization.

Our platforms enable better and timely decision-making at every stage along the entire lifetime of a product

The company’s offerings encompassing glycomics, glycoproteomics and proteomics of biotechnological samples stand out in the market for their accuracy and high quality. The samples include recombinant glycoproteins, microbe/plant-derived oligosaccharides viz. functional food, as well as clinical samples such as blood, milk and other body fluids for the discovery and screening of new biomarkers.

The company invests significantly in R&D to develop, validate, implement and apply novel cutting-edge glycoanalytical methods of a complementary or orthogonal nature, as well as to produce dedicated kits, standards, software tools and databases for this purpose. glyXera is redefining the glycoanalysis space with dedicated systems designed to meet the needs of laborious development concepts, such as DoE, QbD, and quality assessment at all production stages up to product lot release. The systems support the high throughput needs of clinical studies and diagnostics, as well.

When it comes to developing customized glycoanalytical solutions, glyXera is a specialized provider of high-performance glycoanalysis. It possesses the expertise and is flexible enough to customize its high-performance products and services to cater to the specific customer demands. “With our expertise, customer-centric business strategy, plus the high speed, quality and reliability, enabled by our solutions, we take the utmost care of not only R&D but also the entire project for optimal results,” says Dr. Rapp.

In an instance, one of glyXera’s clients had chosen a wrong clone. Having entered the preclinical phase, glycosylation pattern could not be fixed. They needed to return to clone screening without spending heavily or wasting time again. After collaborating with glyXera, the client could acquire additional information about glycosylation already in the discovery phase. Now the client had the ability to choose the accurate later-on production cell line candidate out of more than 500 clones just within three days. In yet another instance, a vaccine candidate showed a very low immune response. With the assistance of glyXera, glycosylation was determined as a major factor for the low response. Having saved the day for many companies over the years, glyXera continues to expand its clientele with superior solutions and value-driven strategies.